Alemtuzumab Budget Impact Analysis in Relapsing-Remitting Multiple Sclerosis in the US

C. Celestin; T. Wandstrat; C.I. Coleman

doi:10.1016/j.jval.2015.03.1637

Alemtuzumab Budget Impact Analysis in Relapsing-Remitting Multiple Sclerosis in the US

Value in Health ◽

10.1016/j.jval.2015.03.1637 ◽

2015 ◽

Vol 18 (3) ◽

pp. A280

Author(s):

C. Celestin ◽

T. Wandstrat ◽

C.I. Coleman

Keyword(s):

Multiple Sclerosis ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Relapsing Remitting ◽

The Us ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Budget Impact Analysis for Daclizumab Beta In Relapsing Remitting Multiple Sclerosis In Italy

Value in Health ◽

10.1016/j.jval.2017.08.1930 ◽

2017 ◽

Vol 20 (9) ◽

pp. A720

Author(s):

F Demma ◽

G Casamassima ◽

E Cocco ◽

R Di Turi ◽

D Paolicelli ◽

...

Keyword(s):

Multiple Sclerosis ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Budget Impact Analysis of Delayed-Release Dimethylfumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy

Value in Health ◽

10.1016/j.jval.2015.09.2619 ◽

2015 ◽

Vol 18 (7) ◽

pp. A700-A701 ◽

Cited By ~ 1

Author(s):

G Furneri ◽

C Marchesi ◽

L Santoni

Keyword(s):

Multiple Sclerosis ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Natalizumab for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients: 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Perspective

Value in Health ◽

10.1016/j.jval.2013.08.1814 ◽

2013 ◽

Vol 16 (7) ◽

pp. A621

Author(s):

A.M. Nishikawa ◽

L. Paladini ◽

A.L. Liamas ◽

C.C. Bueno ◽

O.A.C. Clark

Keyword(s):

Multiple Sclerosis ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Payer Perspective ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Public Payer ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Budget Impact Analysis of Cladribine Tablets for Treatment Of Patients with Relapsing-Remitting Multiple Sclerosis In Bulgaria

Value in Health ◽

10.1016/j.jval.2018.04.1395 ◽

2018 ◽

Vol 21 ◽

pp. S205

Author(s):

S Djambazov ◽

G Slavchev ◽

T Dineva ◽

P Panayotov ◽

T Vekov

Keyword(s):

Multiple Sclerosis ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Budget Impact Analysis of Cladribine Tablets in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in Kingdom of Saudi Arabia

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2019.11.020 ◽

2020 ◽

Vol 37 ◽

pp. 101545

Author(s):

Saeed Abdullah Bohlega ◽

Hajer Al-Mudaiheem ◽

Mansour Alhowimel ◽

Koshu Mahajan ◽

Omneya Mohamed ◽

...

Keyword(s):

Multiple Sclerosis ◽

Saudi Arabia ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Kingdom Of Saudi Arabia ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND37 BUDGET IMPACT ANALYSIS OF ALEMTUZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN HEALTHCARE SOCIAL SECURITY (ESSALUD) IN PERU

Value in Health ◽

10.1016/j.jval.2020.04.930 ◽

2020 ◽

Vol 23 ◽

pp. S265

Author(s):

M. Moreno ◽

J. Arce ◽

A. Cruz ◽

R. Carpio Farro

Keyword(s):

Multiple Sclerosis ◽

Social Security ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Budget Impact Analysis of Fingolimod in Relapsing Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2014.08.872 ◽

2014 ◽

Vol 17 (7) ◽

pp. A393

Author(s):

M. Ruggeri ◽

A. D'Ausilio ◽

R. Lo Muto ◽

S. Cottone ◽

A. Ghezzi ◽

...

Keyword(s):

Multiple Sclerosis ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND9 BUDGET IMPACT ANALYSIS OF CLADRIBINE COMPARED TO THE CURRENT COVERAGE SCHEME IN CHILE TO TREAT PATIENTS WITH HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.08.339 ◽

2019 ◽

Vol 19 ◽

pp. S60

Author(s):

C. Balmaceda ◽

M.A. Espinoza ◽

R. Rojas

Keyword(s):

Multiple Sclerosis ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Highly Active ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND8 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

Value in Health ◽

10.1016/s1098-3015(10)74802-6 ◽

2009 ◽

Vol 12 (7) ◽

pp. A366-A367

Author(s):

O Espallardo ◽

C Crespo ◽

C Polanco ◽

D Nieves

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Impact Analysis ◽

Interferon Beta ◽

Budget Impact ◽

Budget Impact Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND11 Budget Impact Analysis of First-Line Treatment for Relapsing – Remitting Multiple Sclerosis in Spain

Value in Health ◽

10.1016/j.jval.2011.08.477 ◽

2011 ◽

Vol 14 (7) ◽

pp. A319 ◽

Cited By ~ 1

Author(s):

R. Sánchez-de la Rosa ◽

E. Sabater ◽

M.A. Casado

Keyword(s):

Multiple Sclerosis ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Line Treatment ◽

First Line ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis ◽

First Line Treatment

Download Full-text